Roche's faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degenerationGlobeNewsWire • 01/25/21
Genentech's Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular DegenerationBusiness Wire • 01/25/21
FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung DiseaseBusiness Wire • 01/21/21
Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxyGlobeNewsWire • 01/18/21
Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia ProjectThe Motley Fool • 01/14/21
Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimabGlobeNewsWire • 01/12/21
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancerGlobeNewsWire • 01/12/21
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancerGlobeNewsWire • 01/11/21
Roche's Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 yearsGlobeNewsWire • 01/11/21
Roche's novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancerGlobeNewsWire • 01/05/21
Genentech's Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung CancerBusiness Wire • 01/05/21
European Commission approves Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancerGlobeNewsWire • 12/23/20
Roche's faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindnessGlobeNewsWire • 12/21/20
Genentech's Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of BlindnessBusiness Wire • 12/21/20
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE markGlobeNewsWire • 12/15/20
FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosisGlobeNewsWire • 12/14/20